New International Consensus Highlights the Case for Biologic Reassessment in Psoriasis Care (Delphi)

Managing high-cost dermatology biologics requires more than controlling access. A growing international consensus has highlighted the need to reassess treatment intensity after patients with psoriasis achieve remission.

Our latest brief explores the DR Delphi consensus, a global effort involving 62 dermatologists across six continents that established a framework for biologic dose reduction in controlled psoriasis. The evidence is clear: for many patients in sustained remission, structured dose reduction can be safe, effective, and clinically appropriate—creating an opportunity to improve outcomes while addressing rising specialty drug spend for our health plan partners.

Key Highlights:

• Global Consensus: As published in the European Academy of Dermatology and Venereology’s DR Delphi study, international experts concluded biologic dose reduction is appropriate for psoriasis patients whose disease has remained controlled for at least six months.
• ‍The Missing Piece: Most healthcare delivery models lack the monitoring, engagement, and clinical accountability required to operationalize a reassessment model at scale.
• ‍Proven Results: By utilizing Zest Health’s value-based dermatology model, health plans have seen more than 50% of enrolled members successfully transition from high-cost therapies while maintaining clinical outcomes, generating over $17,000 in annual savings per enrollee and delivering a greater than 3:1 ROI.